The record
| Class | glp1 agonist |
|---|---|
| Also known as | Victoza, Saxenda, NN2211, Arg34-Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37) |
| Chain length | - |
| Molecular weight | 3,751.2 Da |
| Half-life | 11-15 hours |
| Route | SC |
| Studied for | Type 2 diabetes (Victoza); Obesity/weight management (Saxenda); CV risk reduction in T2D with CVD |
| Research use | Beta cell preservation, neuroprotection research |
| What has been shown | HbA1c reduction: 1.0-1.5%; Weight loss: 5-8% (Saxenda); CV benefit:; Low hypoglycemia risk |
| How it works | GLP-1 analog with 97% homology to human GLP-1(7-37). C16 fatty acid (palmitic) attached via glutamic acid spacer at Lys26 enables albumin binding for extended half-life. Lys34→Arg substitution. Full GLP-1R agonist activating cAMP pathway: glucose-dependent insulin secretion, decreased glucagon, delayed gastric emptying, appetite suppression. Cardiovascular benefits demonstrated (LEADER trial). |
| Patent status | Novo Nordisk |
| Regulatory status | FDA approved 2010 |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Fat Loss Signaling Environment (affection, 35%)
- Glucose Regulation Support (affection, 100%)
- Appetite Regulation Environment (affection, 84%)
- Cardiovascular risk reduction in T2DM (illness, 60%)
- CV risk reduction in T2D with CVD (illness, 100%)
- Investigational for obesity/chronic weight management and metabolic disease (illness, 40%)
- NASH/fatty liver (illness, 60%)
- Obesity/weight management (illness, 100%)
- Type 2 diabetes (illness, 100%)
- Type 2 diabetes mellitus (illness, 60%)
- Weight management (illness, 60%)
- High blood sugar (symptom, 100%)